The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMercia Asset Regulatory News (MERC)

Share Price Information for Mercia Asset (MERC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 33.80
Bid: 33.00
Ask: 34.60
Change: -0.20 (-0.59%)
Spread: 1.60 (4.848%)
Open: 34.00
High: 34.00
Low: 33.80
Prev. Close: 34.00
MERC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Mercia announces two new direct investments

18 Oct 2022 07:00

RNS Number : 1736D
Mercia Asset Management PLC
18 October 2022
 

RNS

18 October 2022

 

Mercia Asset Management PLC

 

("Mercia", the "Group" or the "Company")

 

Mercia announces two new direct investments - Axis Spine and Nova Pangaea

 

Mercia Asset Management PLC (AIM: MERC), the proactive, regionally focused specialist asset manager with c.£959million of assets under management, is pleased to announce new direct investments into Axis Spine Technologies Ltd ("Axis Spine") and Nova Pangaea Technologies Ltd ("Nova Pangaea").

 

Axis Spine

 

The investment into Axis Spine comes as part of a £10.8million funding round. Mercia has made a direct investment of £3.0million, alongside £3.8million from Mercia's managed funds. MedTex Ventures, a US-based venture capital firm focused on the medical device industry, has invested £3.0million with the remaining £1.0million coming from other external investors. Mercia's managed funds first invested in Axis Spine in 2017.

 

Following this investment, Mercia holds a 11.7% fully diluted direct equity stake in Axis Spine, with funds managed by Mercia holding a further 33.6% fully diluted equity stake.

 

Axis Spine is a Med Tech business delivering spinal implants. Axis has a highly differentiated platform of modular implants, designed to address the increasingly recognised and unmet clinical need of cage subsidence. This technology promises to not only reduce post operative spinal segment collapse, but also improve spinal alignment in patients suffering chronic back pain and spinal deformity.

 

Insertion of Axis' proprietary modular cages requires much less force than conventional implants, they are slimmer and have a wider footprint, thereby reducing the risk of damage to vertebral segment endplates and thus the loss of alignment that impacts one in three patients.

 

Nova Pangaea

 

The investment into Nova Pangaea is part of a £5.3million funding round. Mercia has made an initial direct investment of £2.3million via a convertible loan, alongside £1.0million from Mercia's Northern Powerhouse Investment Fund ("NPIF") and a further £2.0million from co-investors.

 

Nova Pangaea is a Clean Tech business focused on creating biofuels and biochar to address some of the most pressing climate concerns of today. Led by CEO Sarah Ellerby, Nova Pangaea provides a patented process called REFNOVA® that converts woody and agricultural residues into high-value sustainable products that are used to manufacture Sustainable Aviation Fuel ("SAF") and a range of biochemicals. The process also produces Biochar, which is crucial for carbon dioxide removal and soil enhancement.

 

Mark Payton, Chief Executive Officer of Mercia, commented: "These are two businesses we have been excited about for some time, actively supporting them within our managed funds. We are pleased to welcome them onto our balance sheet, where we have significant liquidity to support both in reaching their next stage of maturity. Both embody what we look for in UK regional businesses, combining innovative technology with deep sector specialism to create real-world solutions."

 

"Axis Spine's patented technology has significant benefits over incumbents and, with FDA clearance now received, the team is well placed to move towards commercialisation in the US. We look forward to supporting the team as they scale a unique product.

 

"Nova Pangaea is part of the solution within multibillion dollar markets as industries and governments alike look to transition to cleaner energy. This funding round will enable the business to invest in its growth, including the delivery of its first commercial production facility in 2023. We are excited to be supporting the scaling of Nova Pangaea as it accelerates its commercialisation, signs new partnerships and ramps up its production capabilities."

 

-Ends-

 

For further information, please contact:

 

Mercia Asset Management PLC

Mark Payton, Chief Executive Officer

Martin Glanfield, Chief Financial Officer

www.mercia.co.uk

 

+44 (0)330 223 1430

 

Canaccord Genuity Limited (NOMAD and Joint Broker)

+44 (0)20 7523 8000

Simon Bridges, Emma Gabriel

 

Singer Capital Markets (Joint Broker)

+44 (0)20 7496 3000

Harry Gooden, James Moat

 

FTI Consulting

+44 (0)20 3727 1051

Tom Blackwell, Immy Ransom

mercia@fticonsulting.com

 

About Mercia Asset Management PLC

 

Mercia is a proactive, specialist asset manager focused on supporting regional SMEs to achieve their growth aspirations. Mercia provides capital across its four asset classes of venture, private equity, debt and proprietary capital: the Group's 'Complete Connected Capital'. The Group initially nurtures businesses via its third-party funds under management, then over time Mercia can provide further funding to the most promising companies, by deploying direct investment follow-on capital from its own balance sheet.

 

The Group has a strong UK footprint through its regional offices, university partnerships and extensive personal networks, providing it with access to high-quality deal flow.

 

Mercia Asset Management PLC is quoted on AIM with the EPIC "MERC".

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFLFEDIDLDLIF
Date   Source Headline
9th May 20249:24 amRNSTransaction in Own Shares
8th May 20249:56 amRNSTransaction in Own Shares
7th May 202411:41 amRNSTransaction in Own Shares
3rd May 20249:44 amRNSTransaction in Own Shares
26th Apr 202410:00 amRNSTransaction in Own Shares
25th Apr 20249:29 amRNSTransaction in Own Shares
24th Apr 20249:41 amRNSTransaction in Own Shares
23rd Apr 20249:34 amRNSTransaction in Own Shares
22nd Apr 20249:43 amRNSTransaction in Own Shares
17th Apr 20249:23 amRNSTransaction in Own Shares
16th Apr 20249:44 amRNSTransaction in Own Shares
15th Apr 20249:12 amRNSTransaction in Own Shares
12th Apr 20249:43 amRNSTransaction in Own Shares
11th Apr 20249:35 amRNSTransaction in Own Shares
10th Apr 202411:34 amRNSTransaction in Own Shares
10th Apr 20247:00 amRNSYear end trading summary and date of results
9th Apr 20249:38 amRNSTransaction in Own Shares
5th Apr 20249:25 amRNSTransaction in Own Shares
4th Apr 20249:33 amRNSTransaction in Own Shares
3rd Apr 20249:22 amRNSTransaction in Own Shares
28th Mar 202411:41 amRNSTransaction in Own Shares
27th Mar 20249:57 amRNSTransaction in Own Shares
27th Mar 20247:00 amRNSGrant and variation of Options
26th Mar 202410:31 amRNSTransaction in Own Shares
25th Mar 202412:24 pmRNSTransaction in Own Shares
22nd Mar 20249:01 amRNSTransaction in Own Shares
22nd Mar 20247:00 amRNSDirector/PDMR Dealings
21st Mar 20249:14 amRNSTransaction in Own Shares
21st Mar 20247:00 amRNSMercia secures two further BBB contracts
20th Mar 20249:32 amRNSTransaction in Own Shares
18th Mar 20249:59 amRNSTransaction in Own Shares
15th Mar 20249:04 amRNSTransaction in Own Shares
14th Mar 20247:00 amRNSMercia completes three syndicated funding rounds
13th Mar 202411:24 amRNSTransaction in Own Shares
13th Mar 20247:00 amRNSMercia's Northern VCTs raise £60.0million
12th Mar 20249:46 amRNSTransaction in Own Shares
11th Mar 20249:16 amRNSTransaction in Own Shares
8th Mar 202410:14 amRNSTransaction in Own Shares
7th Mar 202410:15 amRNSTransaction in Own Shares
5th Mar 202410:16 amRNSTransaction in Own Shares
4th Mar 20249:44 amRNSTransaction in Own Shares
1st Mar 202410:11 amRNSTransaction in Own Shares
29th Feb 20247:00 amRNSNew British Business Bank contracts
28th Feb 20248:38 amRNSTransaction in Own Shares
27th Feb 20248:44 amRNSTransaction in Own Shares
26th Feb 20248:49 amRNSTransaction in Own Shares
23rd Feb 20249:25 amRNSTransaction in Own Shares
21st Feb 20249:29 amRNSTransaction in Own Shares
16th Feb 20248:59 amRNSTransaction in Own Shares
15th Feb 20249:31 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.